Meeting
2020 ASCO Virtual Scientific Program
Clinicopathologic features of invasive breast cancer (BC) diagnosed in carriers of germline PALB2, CHEK2 and ATM pathogenic variants.
Authors
Danika Scott
Stanford University School of Medicine, Stanford, CA
Danika Scott , Kerry Kingham , Rachel Hodan , Cindy Ma , Meredith Mills , James M. Ford , Allison W. Kurian , Melinda L. Telli
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Cancer Prevention, Risk Reduction, and Genetics
Track
Prevention, Risk Reduction, and Genetics
Sub Track
Cancer Genetics
Citation
J Clin Oncol 38: 2020 (suppl; abstr 1549)
DOI
10.1200/JCO.2020.38.15_suppl.1549
Abstract #
1549
Poster Bd #
41
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Integrated clinical, pathologic, and genetic data in a racially diverse hereditary breast cancer cohort.
First Author: Kenna Noel Koehler
Poster
2022 ASCO Annual Meeting
DOLAF: An international multicenter phase II trial of durvalumab (MEDI4736) plus olaparib plus fulvestrant in patients with metastatic or locally advanced ER-positive, HER2-negative breast cancer selected using criteria that predict sensitivity to olaparib.
First Author: Severine Guiu Lahaye
Poster
2023 ASCO Annual Meeting
Twenty-one gene recurrence scores in individuals with breast cancer associated with CHEK2 and ATM germline pathogenic variants.
First Author: Payal Deepak Shah
Poster
2023 ASCO Annual Meeting
A phase II study of olaparib (AZD2281) in patients (Pts) with metastatic/advanced urothelial carcinoma and other genitourinary (GU) tumors with DNA-repair defects.
First Author: Elias Chandran